Trial Information

Urine Prostaglandin-M(PGE-M) in Ovarian Cancer

OBJECTIVES:

- Determine the level of prostaglandin E_2 metabolite (PGE-M) in 24-hour urine samples
collected prior to surgery or chemotherapy from patients with ovarian cancer.

- Determine cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) expression by western
blot and immunohistochemistry (IHC) in ovarian tumor tissue samples and matched normal
ovarian tissue samples, if available, from these patients.

- Correlate urine PGE-M levels with corresponding tissue COX-1 and COX-2 levels in urine
and tissue samples from these patients.

OUTLINE: This is a pilot study.

Patients submit 24-hour urine specimens prior to surgery for evaluation of urinary levels of
prostaglandin E_2 metabolite (PGE-M).

Patients also undergo assessment of tissue obtained at the time of surgery, including
ovarian tumor tissue, normal surface ovarian epithelium tissue (if available), and fixed
tissue embedded in a paraffin block. Tissue samples are analyzed by western blot and IHC for
cyclooxygenase-1 and cyclooxygenase-2 expression.